Mustang Bio Inc. (MBIO) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Per the Roarable RQD rating, MBIO carries an RQD Score of 39 and a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars, the fundamental cash engine scores 4 / 20 (ROIC -35%; FCF yield 0%), indicating that the business is not currently generating returns on capital or free cash flow. The whale 13F flow pillar scores 10 / 20 for institutional accumulation and options positioning, a middling reading. The insider conviction pillar scores 5 / 20 on SEC Form 4 and Congressional PTR cluster flow, signaling weak insider-side support. The macro regime fit pillar scores 10 / 20, with a Beta of 1.0 and a sector sensitivity profile. The forensic balance sheet pillar scores 10 / 20, reflecting an Altman Z of 2.5, a Piotroski F of 2/9, and a Debt/Equity of 0.5.

For a prospective investor, the upside case rests almost entirely on whether the company can convert its cash position into a durable operating path, since current cash flow and returns are negative. Valuation tradeoffs are sharp: with a market capitalization of $3.0M and a share price of 0.39, the equity is priced at a very small scale relative to the operating losses recorded in the SEC financials. The rating's weakest pillars point to the core risks of dilution, continued cash burn, and limited institutional or insider conviction. Any reading of the stock should weigh these structural factors against the short-term price momentum shown in the market data.

Per the SEC financials, operating and net losses narrowed from $-51.6M in FY 2023 to $-1.9M in FY 2025, and reported cash rose from $6.8M in FY 2024 to $17.3M in FY 2025. Gross, operating, and net margins are each 0% per the market data, and ROIC is -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, per the Roarable RQD rating. Debt/Equity is 0.5, and the SEC table lists debt as N/A for each period.

The news wire lists five items, all tagged to MBIO and all flagged YELLOW under the MARKET WIRE impact label. Headlines include a TradingView estimates item, a Yahoo Finance UK seasonal returns item, two TradingKey most-active and unusual-volume items, and an ad-hoc-news.de item titled "Mustang Bio gets Nasdaq reprieve," which states the stock needs USD 1.00 bids. The summaries are generic and do not describe the substance of any catalyst. The Butterfly supply-chain graph reports no supply chain and no proprietary signals. Key risk watch item: the Nasdaq bid-price requirement referenced in the ad-hoc-news.de headline, given the 0.39 share price.

• What products or clinical programs generate the company's R&D spending, and what is their development stage?
• What is the company's current debt obligation, since the SEC financials list debt as N/A?
• What is the cash runway implied by FY 2025 cash of $17.3M against FY 2025 free cash flow of $-5.3M?
• What steps has the company taken or proposed in response to the Nasdaq bid-price requirement referenced in the news wire?
• Which shareholders or institutions hold the stock, given that the holders section is empty?